Revolution Medicines RVMD
Nasdaq · Biological Products, (No Diagnostic Substances)$161.20+1.11%Nov 20 close · Databento
Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
2 stories have a settled next close so far (2 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoRevenue$0
True FCF (ex-SBC)$-1.0B −60.9%
ROIC-95.1%
EPS, diluted$-5.95 −66.2%
Modern Valuation (EOD)
Market Cap—
Enterprise Value—
EV / True FCF—
EV / FCF—
EV / Gross Profit—
EV / EBIT—
EV / Sales—
P / E (GAAP)—
P / FCF—
P / Oper. CF—
P / Book—
Owner & Cash Yields
True FCF Yield—
FCF Yield—
Owner Earn. Yield—
Earnings Yield—
Shareholder Yield—
Buyback Yield—
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh$-4.22
EPS (diluted)$-5.95
Compounder & Returns
Rule of 40—
ROIC-95.1%
Cash ROIC (CROIC)-73.5%
GP / Assets—
ROE—
ROA—
Gross Margin—
Oper. Margin—
Net Margin—
FCF Margin—
True FCF Margin—
Quality & Dilution
Cash Conversion—
Accrual Ratio−9.9%
SBC % of FCF—
SBC % of Rev—
Reinvest. Rate—
Sales Growth Y/Y—
Sales 3Y CAGR—
EPS Growth Y/Y−66.2%
FCF Growth Y/Y−60.9%
FCF 3Y CAGR—
Share Change Y/Y+13.3%
Balance Sheet & Scale
Revenue (FY)$0
Gross Profit (FY)—
Oper. Income (FY)$-1.2B
GAAP Net Income—
True FCF (ex-SBC)$-1.0B
Cash & Equiv$388.6M
Total Debt—
Net Cash (Debt)$388.6M
Net Cash % MCap—
Debt / FCF (yrs)—
Current Ratio7.14216.29M sh
Price & Technicals (EOD)
Perf Week−6.44%
Perf Month−14.11%
Perf Quarter−23.81%
Perf Half Y+6.36%
Perf YTD+9.50%
SMA 20 Dist−11.06%$181.25
SMA 50 Dist−15.17%$190.02
SMA 100 Dist−16.96%$194.13
Window High−27.11%$221.15
Window Low+13.67%$141.81
RSI (14) · Vol35.665%v
Income Distribution & Cash Flow ConversionHow every dollar of RVMD revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
Where Every $100 of Revenue Goes (FY2023)
Cost of Revenue (COGS)$0 ($0.0 / $100)
R&D Reinvestment$423.1M ($100.0 / $100)
Operating Expenses$75.6M ($100.0 / $100)
Tax & Non-Operating$0 ($0.0 / $100)
Net Profit Kept$-436.0M ($0.0 / $100)
Earnings Quality: GAAP Profit → True Owner Cash (FY2023)
GAAP Net Income$-436.0M (-3765.1% margin)
Operating Cash Flow (OCF)$-350.6M(-3027.4% of rev)
Less: Capital Expenditures−$7.7M(66.7% of rev)
Standard Free Cash Flow (FCF)$-358.3M(-3094.1% margin)
Less: Stock-Based Comp (SBC)−$61.8M
True FCF (Owner Cash ex-SBC)$-420.1M(-3627.6% of rev)
Revenue by fiscal year
Operating leverage — margins
GrossOperatingNet
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $29.4M | $35.4M | $11.6M | $0 | $0 | — | — | |
| Research & Development (R&D) | $186.9M | $253.1M | $423.1M | $592.2M | $987.3M | +66.7% | +51.6% | |
| Total Operating Expenses | $217.4M | $293.7M | $498.8M | $689.5M | $1.2B | +71.5% | +52.7% | |
| Operating Income (EBIT) | $-188.0M | $-258.3M | $-487.2M | $-689.5M | $-1.2B | −71.5% | — | |
| Interest Expense | $12,000 | $0 | $0 | $0 | $24.2M | — | +570.3% | |
| Income Tax Expense | $0 | $-420,000 | $-3.5M | $-753,000 | $0 | +100.0% | — | |
| GAAP Net Income | $-187.0M | $-249.0M | $-436.0M | $-600.0M | $-1.1B | −88.5% | — | |
| Diluted EPS | $-2.57 | $-3.08 | $-3.86 | $-3.58 | $-5.95 | −66.2% | — | |
| Diluted Shares | 72.8M | 80.6M | 113.1M | 167.7M | 190.1M | +13.3% | +27.1% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $110.2M | $163.1M | $699.2M | $546.8M | $388.6M | −28.9% | +37.0% | |
| Inventory | $11.0M | $11.0M | $11.0M | $11.0M | $0 | −100.0% | — | |
| Total Current Assets | $589.8M | $660.2M | $1.9B | $2.3B | $2.1B | −10.9% | +37.0% | |
| Total Assets | $738.0M | $811.9M | $2.1B | $2.6B | $2.4B | −8.0% | +33.6% | |
| Total Current Liabilities | $60.4M | $62.0M | $143.9M | $163.9M | $290.4M | +77.2% | +48.1% | |
| Total Liabilities | $135.4M | $126.7M | $235.5M | $293.1M | $723.2M | +146.7% | +52.0% | |
| Stockholders' Equity | $602.6M | $685.2M | $1.8B | $2.3B | $1.6B | −28.0% | +28.3% | |
| Net Cash / (Net Debt) | $110.2M | $163.1M | $699.2M | $546.8M | $388.6M | −28.9% | +37.0% | |
| Invested Capital | $492.3M | $522.0M | $1.1B | $1.7B | $1.2B | −27.7% | +26.0% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $-147.2M | $-224.4M | $-350.6M | $-557.4M | $-897.7M | −61.0% | — | |
| Depreciation & Amortization (D&A) | $3.1M | $4.0M | $5.0M | $6.2M | $7.4M | +19.4% | +24.5% | |
| Stock-Based Compensation (SBC) | $20.7M | $31.2M | $61.8M | $79.2M | $118.4M | +49.5% | +54.6% | |
| Capital Expenditures (CapEx) | $6.5M | $10.8M | $7.7M | $10.3M | $16.0M | +55.1% | +25.1% | |
| Free Cash Flow (FCF) | $-153.7M | $-235.2M | $-358.3M | $-567.7M | $-913.7M | −60.9% | — | |
| True FCF (ex-SBC Owner Cash) | $-174.4M | $-266.4M | $-420.1M | $-646.9M | $-1.0B | −59.5% | — | |
| Dividends Paid | — | — | — | — | $0 | — | — | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.
On the Wire
what RVMD did at the next close after each storySep 14
FDA grants Revolution Medicines breakthrough status for pancreatic drug
−0.12%GlobeNewswire · 4:05 PM ET
Aug 26
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
+1.92%GlobeNewswire · 3:07 PM ET
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.